In a significant move to enhance diabetes care accessibility, Mankind Pharma has introduced Empagliflozin at a groundbreaking price, making it one of the most affordable options available. The 10 mg variant is priced at INR 5.49 per tablet, while the 25 mg variant costs INR 9.90 per tablet.

Mr. Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, emphasized that the initiative aims to eliminate cost barriers while maintaining international quality standards. “With this launch, Mankind Pharma has once again broken cost barriers by offering a product that combines international quality with affordability. By introducing Empagliflozin at such competitive prices, we are ensuring that cost is no longer an obstacle to access. Aligned with our vision towards building a healthier Bharat, we remain committed to making high-quality medicines affordable and accessible to every patient in need,” he stated.

To maximize its market penetration, Mankind Pharma has strategically deployed two separate teams to promote the drug under distinct brand names. This approach is expected to broaden its reach in the highly competitive diabetes segment. Furthermore, the company’s extensive distribution network will play a crucial role in ensuring that patients in both urban and rural areas benefit from this price innovation.

Empagliflozin is a widely prescribed medication for managing type 2 diabetes, helping to control blood sugar levels and reduce the risk of cardiovascular complications. By offering it at a significantly lower price, Mankind Pharma aims to improve treatment adherence among patients who might otherwise struggle with the financial burden of long-term diabetes management.

With diabetes prevalence rising across India, particularly in underserved regions, this move is expected to have a profound impact on public health by making life-saving medication more accessible to millions.